Earnings improvement at listed companies Listed companies' pre-tax profit grew substantially in 2003. IGBM companies, which posted a loss of 3.099 billion euros in 2002, recorded a pre-tax profit of 35.229 billion euros in 2003 1 ; . The bulk of the improvement in listed companies' earnings was due not only to an increase in ordinary profit but also to a reduction in extraordinary losses at companies with sizeable investments in Latin America. The telecommunications sector performed superbly: from a loss of 25.470 billion euros in 2002 to a profit of 5.628 billion euros in 2003 due to narrower extraordinary losses at the Telefnica Group 2 ; . The banking sector also substantially reduced extraordinary expenses related to financial investment write-downs 3 ; in Latin America so, despite lower operating profit, pre-tax profit increased by 17.5% to 10.811 billion euros. The gain by two other leading sectors was due to the general economic improvement. Profits in the energy sector increased by 21.5% to 9.498 billion euros due mainly to higher oil prices, which boosted earnings at Repsol YPF 4 ; and Cepsa. The construction sector reflected strong performance in Spain and doubled pre-tax profit to 4.297 billion euros. Two sectors registered a decline in 2003: the advertising, press and television sector recorded a loss of 179.8 million euros due to heavy losses at Sogecable as a result of restructuring costs related to the digital platform merger, whereas the beverages and tobacco sec.
The Clinical Laborato In provement Anrendment CLIA ; of 1988 requires laboratories and other facilities that test huraan specimens to obtain either a CLIA Waiver or CLIA Certtficate in order to obtain reimbursement from the Medicare and Medicaid AHCCCS ; programs. In addition, they must meet all the requirements of 42 CFR 493, Subpart A. To comply with these requirements, AHCCCSA requires all clinical laboratories to provide verification of CLIA Licensure or Certificate of Waiver dunng the provider registration process. Failure to do so shall result m enfier a termination of an active provider ID ntunher or demal of initial registration. These requirements apply to all clinical laboratories, Pass through billing or other similar actlv0ies with the intent of avoiding the above requirements are prohibited. The Contractor may not reimburse providers who do not comply with the above requirements, CLIA of 1988; 42 CFR 493, Subpart A ; 6. COMPLIANCE %1TH AHCCCSA RULES RELATING TO AUDIT AND INSPECTION.
From Rockford Gastroenterology Associates R.L.B., J.J.V., J.F.J., R.L.G. ; and the University of Illinois College of Medicine at Rockford R.L.B., J.J.V., A.S.D., J.F.J., R.L.G. ; -- both in Rockford. Address reprint requests to Dr. Barclay at Rockford Gastroenterology Associates, 401 Roxbury Rd., Rockford, IL 61107, or at drbarclay rockfordgi . N Engl J Med 2006; 355: 2533-41.
Experimental exposures to graded doses of triactinomyxons provided the ability to assess the relative susceptibility of brown and rainbow trout to Myxobolus cerebralis infections. Brown trout were clearly more resistant than rainbow trout with respect to the onset of clinical signs, risk and severity of infections, and production of spores. These differential responses to the parasite in each fish species aid in explaining why certain wild brown trout populations escape the severe negative impacts observed in wild rainbow trout. However, experimental exposures to high doses of triactinomyxons 1000 and 10 000 per fish ; can overwhelm the innate resistance of brown trout, a finding that points to high exposure rates in locations where wild brown trout have suffered negative impacts due to whirling disease. Curiously, the disease that results from high exposure rates of brown trout differs from that seen in rainbow trout both in the absence of the radical swimming behavior and a lack of increasing parasite bur.
Clofarabine cytarabine
Before treatment started, all patients were randomly assigned by phone call to the statistical center. Patients then received the first induction course, consisting of cytarabine 100 mg m2 by continuous intravenous IV ; infusion daily on days 1 and 2 and by 30-minute infusion every 12 hours on days 3 through 8, daunorubicin 60 mg m2 by 30-minute IV infusion on days 3, 4, and 5, and 6-thioguanine 100 mg m2 administered orally every 12 hours on days 3 through 9 TAD ; , as published.9, 17 On day 16 of therapy, bone marrow was examined for the percentage of blasts. On day 21, all patients younger than 60 years of age received a second induction course double induction ; . In the older patients, the second course was given only if bone marrow contained 5% blasts on day 16, irrespective of its cellularity. For the second course, cytarabine 3 age 60 years ; or 1 age 60 years ; g m2 was administered by 3-hour IV infusion every 12 hours on days 1 through 3, with mitoxantrone 10 mg m2 by 30-minute IV infusion on days 3, 4, and 5 HAM ; .18 If bone marrow continued to contain 5% blasts after HAM or if similar features reappeared in weekly bone marrow sampling, then the patient was treated off study. After entering complete remission CR ; , patients started with a consolidation course of TAD 2 to 4 weeks later. After TAD, patients were given either maintenance chemotherapy or one course of IC according to their initial randomization. Although maintenance chemotherapy started at reachievement of CR criteria after TAD consolidation, IC started 6 weeks later. Maintenance chemotherapy was as published, 9, 11 with monthly courses of cytarabine 100 mg m2 injected subcutaneously every 12 hours for 5 days, as with a second drug, daunorubicin, 45 mg m2 by 30 minute IV infusion on days 3 and 4 course 1 ; , 6-thioguanine 100 mg m2 orally administered every 12 hours on days 1 to 5 course 2 ; , cyclophosphamide 1 g m2 day 3 course 3 ; , 6-thioguanine again course 4 ; , and restarting with course 1. If absolute neutrophil count decreased to less than 500 L and or platelets to less than 20, 000 L after each of two sequential courses, the doses of all antileukemic drugs were reduced by 50%, permanently. Using this policy it was found that from the third maintenance course, almost all patients required adjustment and continued at 50% dosage, whereas further reductions were possible accordingly. Maintenance chemotherapy continued until patients had been in remission for 3 years, 11 which was largely fulfilled in the majority of patients achieving RFS of at least 3 years. IC consisted of cytarabine 1 age 60 years ; or 0.5 age 60 years ; g m2 by 3-hour IV infusion every 12 hours on days 1, 2, 8, and 9, with mitoxantrone 10 mg m2 30-minute IV infusion on days 3, 4, 10, and 11 sequential HAM [S-HAM] ; .19 As alternative to maintenance or IC chemotherapy, allogeneic transplantation in first CR was offered to all patients up to 50 years of age who had a histocompatible sibling.
Cytarabine ndc
EOC Surfactants has launched three new ingredients. EurAmid N2 is a unique mild and naturally derived multifunctional thickening surfactant specially designed for easy and effective replacement of Cocamide DEA. EurAmid N2 not only viscosifies surfactants based formulations, it also stabilizes foam and provides emolliency. Europacif 2150 is a new versatile opacifier designed for giving a milky appearance to a wide range of personal care products such as shampoos, shower gels and bath foams. Europacif 2150 is effective at very low dosage levels and is suitable for use across a broad pH range. EuroNac AMF Ultra is a new innovative amphoteric pearlescing agent. EuroNac AMF Ultra is not only free of anionics but it is also free of ethoxylated material. EuroNac AMF Ultra may be used in any kind of applications: standard formulations, LES-free products, EO-free recipes and also cationic formulations and cytomel.
This is a clinical trial, a type of research study. Your study doctor will explain the clinical trial to you. Clinical trials include only people who choose to take part. Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation. You are being asked to take part in this study because you have nasopharyngeal cancer that has not spread to other parts of your body.
Data from trials NAIA2009 and NAIB2009 were amalgamated by the drug company before analysis. * The higher the score maximum 5 ; , the higher the methodological quality. Pooled odds ratio 0.19 0.09 to 0.38 . Pooled odds ratio 0.26 0.08 to 0.84 . Included for completeness only licensed dosage considered by the review ; . Members of household in which one individual had contracted influenza-like illness index case ; and who were given a neuraminidase inhibitor prophylactically while the index case was treated with a neuraminidase inhibitor and cytoxan!
All infection rate p 0.12 ; as well as grade III IV infection frequency p 0.23 ; among patients treated with DA-7 or DAC-7 regimen. Microbiologically or clinically documented bacterial infections occurred in 127 41% ; patients, including 67 43% ; DA-7 patients and 60 39% ; DAC-7 patients p 0.5 ; . A total of 71 23% ; episodes of bacteremia were found, including 60% Gram-positive, 30% Gram-negative, and 10% mixed blood cultures. Forty-two 27% ; patients in the DA-7 group and 29 19% ; patients in the DAC-7 group had bacteremia p 0.06 ; . Microbiologically documented fungal infections occurred in 42 13% ; patients, including 16 10% ; DA-7 patients and 26 17% ; DAC-7 patients p 0.06 ; . A total of 5 2% ; episodes of fungemia were reported and its frequency was similar in both study arms. Viral infections were observed in 35 11% ; patients and it did not occur more often in patients receiving DAC-7 therapy when compared to patients treated with DA-7 regimen p 0.6 ; . At univariate analysis, AML subtypes according to FAB classification, preceding myelodysplastic syndrome, age, sex, induction treatment arm, response to induction therapy, the presence of Hickman's catheter, and the use of antimicrobial prophylaxis were not significantly associated with the risk of infection. In all, 11 7% ; patients died of infection'related complications in the DA-7 arm compared to 17 11% ; in the DAC-7 arm p 0.4 ; Conclusions. Addition of cladribine to daunorubicin and cytarabine did not result in significantly more infectious complications than standard treatment with daunorubicin and cytarabine in adult AML patients.
Idarubicin and cytarabine
Image 1 Histopathologic findings in a patient who became negative for t 9; 22 ; after treatment with imatinib mesylate. A, The bone marrow from patient 1, who became negative for t 9; 22 ; by months of follow-up, initially was hypercellular and showed typical features of chronic-phase chronic myeloid leukemia CML ; H&E, original magnification 40 ; . B, The aspirate had findings characteristic of CML, including a marked myeloid predominance and basophilia Wright-Giemsa, original magnification 600 ; . C, After initiation of treatment with imatinib mesylate, the marrow cellularity dropped to a nadir of 5% at 3 months H&E, original magnification 40 ; . D, The bone marrow was moderately hypocellular by 9 months H&E, original magnification 40 ; . E, By months of follow-up, the bone marrow showed no morphologic evidence of CML. The cellularity was mildly decreased H&E, original magnification 100 ; . F, The bone marrow aspirate at 21 months of follow-up demonstrated normal hematopoiesis Wright-Giemsa, original magnification 600 and dacarbazine.
Hospital services for people with arthritis and related conditions . Age- and sex-standardized rate of hospital admissions, by diagnosis, Canada, 19942000 . Rate of arthritis-related hospital admissions per 100, 000 population, by age and sex, Canada, 2000 . Age- and sex-standardized rate of medical admissions per 100, 000 population for people with an arthritis-related condition, by province, Canada, 1994-2000 Number of inpatient and outpatient arthritis-related orthopedic procedures in selected provinces, Canada, 1994-2000 Number of arthritis-relevant orthopedic procedures in selected provinces, Canada, 2000 . Number of total hip and knee replacements per 100, 000 population, Canada, 19942000 . Age-standardized rate of total hip or knee replacement per 100, 000 population, by sex, Canada, 1994-2000 Number and crude rate of total knee replacements per 100, 000 population, by age, Canada, 2000 . Number and crude rate of total hip replacements per 100, 000 population, by age, Canada, 2000.
LACTIC DEHYDROGENASE LDH ; Method: Fasting: Specimen: Enzymatic TRIS NAD No Gold Top tube, DO NOT REFRIGERATE. This specimen must remain at room temperature. The lab is unable to add-on to previously drawn, refrigerated blood. 100-190 U L Useful in the diagnosis and treatment of myocardial and pulmonary infarction. They may also be used to monitor extensive cancer and cancer This test is performed daily in Core lab. 83615 and daclizumab.
1. Hot Poured Elastic Type 3720 Visual Inspection 1 per lot 5 kg 3723 10 lb. ; 3725 Usually inspected at source. Call Laboratory at 651 ; 779-5548 for approval. 2. Silicone Joint Sealer Approved Products Only * * Approved products only. No routine sampling required. Spot Check sampling as District Materials Engineer directs. 3. Preformed Elastomeric Type3721 Visual Inspection 2415 * 1 per 1, 000 m 3, 000 LF ; for 2 m or 2403 each lot or sub-lot or fraction 6 ft ; * Field Inspection Report Lot Numbers Only ; 4. Preformed 3702 Visual Inspection 1 per shipment of each type 0.25 m and thickness 2 Sq Ft ; Will carry "Inspected" tag if approved prior to shipment.
Cytarabine dosage
We thank Mr. Greg Olson and Ms. Christine Cook from the Surgical-Medical Research Institute of University of Alberta for technical assistance. This study was supported by the Canadian Arthritis Network National Networks of Excellence and dactinomycin.
1. Co-Account Owner Information Complete this Schedule only if you are opening a Non-Registered Joint Account.
Corroborated by the results of the ongoing GMALL study 05 93, including 47 patients with pro-B ALL who received identical consolidation with HD cytarabine and mitoxantrone as in study 04 89. In this study, comparable with the results of study 04 89, a CR rate of 81% and a relatively high probability of CCR 0.55 at 2 years ; could be achieved Hoelzer et al, unpublished observations ; . Interestingly, recent studies with the 3- 4, 5dimethyl-thiazol-2-yl ; -2, 5 diphenyl tetrazolium bromide MTT ; assay indicate a high antileukemic activity of cytarabine as compared with corticosteroids, L-asparaginase, and anthracyclines in leukemic blasts from pro-B ALL patients R. Pieters, personal communication, April 1997 ; , thus supporting our treatment results in studies 04 89 and 05 93. High-risk patients with a common or pre-B ALL phenotype, as compared with pro-B ALL, had a similar probability of CCR in study GMALL 03 87 and a significantly inferior probability of CCR in study 04 89. These data suggest that this subgroup of B-lineage ALL, which, however, includes a large number of Ph patients, did not benefit from an intensification of consolidation treatment. Secondly, the division of pro-B ALL patients into different subgroups according to the genotypic features of their leukemic blasts allowed us to demonstrate that a portion of adult patients with a t 4; 11 ; and or MLL-AF-4 transcripts may achieve long-term remission and probably cure, after having received intensive postremission treatment. Our recent observations, applying RT-PCR analyses to detect MLL-AF-4 rearrangements in 5 adults with pro-B ALL in CR, all of whom exhibited MLL-AF-4 transcripts at diagnosis and lacked evidence of minimal residual disease 8 to 52 months after diagnosis, are in line with this statement.49 These results are in contrast with previous reports, mainly based on surveys of literature, 28, 29, 34 or comprising a relatively small number of patients with, usually, heterogeneous treatment.31, 32, 42, 43 These reports unequivocally suggested that, of patients with a t 4; 11 ; , adults had the worst prognosis, with median survivals of 7 months, 31 even with contemporary intensive treatment strategies, thus justifying the use of BMT or innovative treatment approaches.34 Thirdly, as opposed to the French LALA87 study group that recently published their results in 45 adult patients with CD10 B-lineage ALL, 13 our data strongly suggest that the distinction between CD10 pro-B ALL and CD10 common or pre-B ALL provides useful information for tailoring treatment strategies according to specific subtypes of ALL. Adult patients with pro-B ALL and 11q23 translocations, in our series exclusively t 4; 11 ; , represent a distinct clinicopathologic entity that can be recognized easily based on its immunophenotypic and genotypic features. Obviously, further studies, applying cytogenetic and, especially, molecular analyses, are needed to better characterize the biological and clinical features of adult pro-B ALL patients whose leukemic blasts lack 11q23 translocations, display 11q23 rearrangements not caused by a t 4; show deletions and inversions affecting the 11q23 region but do not involve MLL rearrangements. Recent results from the Groupe Francais de Cytogenetique Hematologique suggested that adult patients with breakpoints on 11q23 not involving a t 4; 11 ; deletions of 11q23 had the same poor outcome as patients with a t 4; 11 ; .15 In contrast, a recent study of 17 childhood ALL cases with a deletion or inversion affecting the 11q23 region without and dalteparin.
Free Cytarabine
TIECKE, RICHARD WILLIAM, Armed Forces Inst. Path., 7th & Independence Ave., S.W., Washington, D.C. Oral pathology. Muscatine, Iowa, Apr. 5, '17. B.S., U. Iowa, '41; D.D.S., '42; M.S., '47. Fel., U. Iowa, '46- '47; resident, Zoller Dent. Clin. U. Chicago, '47- '49; resident, Armed Forces Inst. Path., '49-52. U.S.A., '42-'46; Reg. Army, '47-; Major, Armed Forces Inst. Path., '51-. Wash. Soc. Path.; fel., Am. Acad. Oral Path.; A.D.A. Socalled mixed tumors of the salivary glands; intra-oral squamous cell carcinoma. TILDEN, EVELYN BUTLER, Northwestern U. Dent. Sch., Chicago, Ill. Biochemistry, bacteriology. Lawrence, Mass., March 28, '91. A.B., Pembroke Brown Univ. ; , '13; A.M., Columbia, '26, Ph.D., '29. Asst. path. and bact., Rockefeller Inst., '28-'31; asst. prof. bact., Colo. Agr. Col., '31- '32; assoc. res. bact., Med. Sch., Northwestern, '32- '36 bact., Nat. Inst., Health, U.S.P.H.S., '36- '42; assoc. prof. bact., Dent. Sch., Northwestern, '42- '48; prof., '48-. A.A.A.S.; A.C.S.; Soc. Am. Bact.; Am. Pub. Health Asn.; Wash. Acad.; Sigma Xi. Parasitic protozoa; spirochetes; viruses of inclusion blennorrhea and herpes; preparation of rare carbohydrates by bacterial action; antibiotics and oral bacteria; evaluation of disinfectants; tests for acidogenic bacteria. TOVERUD, GUTTORM, Norges Tannlegehogskole, Gjetmyrsveien 69, Oslo, Norway. Dental caries. Urskog, Norway, Apr. 30, '96. Tannlege from the State Dent. Inst. Norway, '19; spec. courses at Harvard Dent. and Med. Sch. and Washington U. Med. Sch., '21- '23; studied in the Res. Lab., Forsyth Dent. Infirm. Child., '21-'22; spec. studies physiological dept. U. Nor and cytarabine.
Establish an accurate diagnosis, considering other psychotic disorders in the differential diagnosis because of the major implications for short- and long-term treatment planning. If a definitive diagnosis cannot be made but the patient appears prodromally symptomatic and at risk for psychosis, reevaluate the patient frequently and damiana.
Hymns that correspond to the sacred Bible 10 ; . The hymns are simple words put to music, considered to be "received" by people through channeling - Though he initially received "chamadas" calls ; , which were melodies without words, that he whistled; after some time , Mestre Irineu began receiving the hymns that were to compose his "Hinrio do Cruzeiro", which is considered to be the basis of the "Santo Daime" doctrine. They speak of Mestre Irineu's visions , featuring "divine beings" from the "celestial court" including a wide range of spirits from the Christian, Indian and African pantheons. Little is known of Mestre Irineu's spiritual development in the early years following his first experiences with Daime. We know, however, that, in 1931 when he had already parted company with the Costa brothers, he started to organize ayahuasca sessions involving a few other people. These consisted basically of concentration sessions and of talks in which he transmitted the teachings that he received from the Daime . It is also known that his interests 53.
Side effects of Cytarabine
REFERENCES 1. Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986; 314: 10651069. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997; 337: 223-229. Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999; 17: 284292. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038-1042. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant. 1996; 17 Suppl 3: S1-3. 7. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996; 17 Suppl 3: S5-6. 8. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994; 84: 2036-2043 Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, Storb R, Thomas ED. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood. 1999; 94: 3960-3962. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Appelbaum FR, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997; 89: 3055-3060 Elmaagacli AH, Beelen DW, Opalka B, Seeber S, Schaefer UW. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after and danaparoid.
Cytarabine intrathecal administration
1. Hoelzer D, Thiel E, Loffler B, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1989; 71: 123-131. Gaynor J, Chapman D, Little C, et al. A causespecific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol. 1988; 6: 1014-1030. Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation and maintenance chemotherapy. Blood. 1989; 73: 57-63. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin and dexamethasone regimen in adults with acute lymphocytic leukemia. J Clin Oncol. 1990; 8: 994-1004. Linker CA, Levitt LJ, O'Donnel M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991; 78: 2814-2822. Larson RA, Dodge RK, Burns CP, et al. A fivedrug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood. 1995; 85: 2025-2037. Dekker AW, van't Veer MB, Sizoo W, et al. Intensive postremission chemotherapy without maintenance therapy in adult acute lymphoblastic leukemia. J Clin Oncol. 1997; 14: 476-482. Todeschini G, Tecchio C, Meneghini V, et al. Estimated 6-year event free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia. 1998; 12: 144-149. Daenen S, van Imhoff GW, van den Berg E, et al. Improved outcome of adult acute lymphoblastic leukaemia by moderately intensified chemotherapy which includes a "pre-induction" course for rapid tumour reduction: preliminary results on 66 patients. Br J Haematol. 1998; 100: 273-282. Fiere D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol. 1993; 11: 1990-2001. De Witte T, Awwad B, Boezeman J, et al. Role of allogenic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma in first remission. Bone Marrow Transpl. 1994; 14: 767-774. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant Interleukin-2 after autologous bone marrow transplantation. Blood. 1995; 86: 1619-1628. Mandelli F, Annino L, Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow up. Br J Haematol. 1996; 92: 665-672. Weiss MA, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remission in adult acute lymphoblastic leukemia ALL ; without vincristine or prednisone. J Clin Oncol. 1996; 14: 2480-2485. GIMEMA Infection Program. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med. 1991; 115: 7-12. Bennett JM, Catowsky D, Daniel MT, et al. The French-American-British FAB ; Cooperative Group. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlation. Br J Haematol. 1981; 47: 553-558. De Rossi G, Grossi C, Foa R, et al. Immunophe` notype of acute lymphoblastic leukemia cells: the experience of the Italian Cooperative Group GIMEMA ; . Leuk Lymphoma. 1993; 19: 221-228. Mandelli F, Annino L, Ciolli S, et al. Philadelphia Ph1 ; positive acute lymphoblastic leukemia ALL ; in adults: interim analysis of the GIMEMA ALL 0288 pilot study [abstract]. Blood. 1992; 82: 219a. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Stat Assoc. 1958; 53: 457-481. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: analysis and examples. Br J Cancer. 1977; 35: 1-39. Simon R, Lee YJ. Nonparametric confidence limits survival probabilities and median survival time. Cancer Treat Rep. 1982; 66: 37-42. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: Wiley; 1989. 23. Cox DR. Regression models and life-tables. J R Stat Soc [B]. 1972; 34: 187-220. SAS Technical Report P-229, SAS STAT Software: Changes and Enhancements, Release 6.07. Cary, NC: SAS Institute; 1992: 243, 433. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999; 94: 1209-1217 and cytomel.
Cytarabine neuropathy
Cytarabine blood brain barrier
Biochemistry vanderbilt, oxytocin unit, canavan disease history, influenza complications and foramen monroe. Randomly amplified polymorphic dna rapd analysis, minor kings, blind date fart and cervical dysplasia while pregnant or radial stress.
Cytarabine hcl
Cytarxbine, cytarab8ne, cytarabime, cyfarabine, cyharabine, ytarabine, c7tarabine, cytarabibe, cytaabine, cytarabone, cjtarabine, cytarabin, cytarabinr, cytarabie, cytarqbine, cytarab9ne, cytarbaine, cytarabien, cytarabinf, ccytarabine.
Cytarabine vesicant
Clofarabine cytarabine, cytarabine ndc, idarubicin and cytarabine, cytarabine dosage and free cytarabine. Side effects of cytarabine, cytarabine intrathecal administration, cytarabine neuropathy and cytarabine blood brain barrier or cytarabine hcl.
|